Publication | Open Access

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial

Translational MedicineBintrafusp AlfaMedicineImmunologyClinical TrialsImmune Checkpoint InhibitorPharmacotherapyCancer TreatmentOncologyRadiation OncologyPhase 1Novel TherapyExpansion CohortHealth Sciences